Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).

@article{Gmez2003UseOC,
  title={Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).},
  author={Susana Guzm{\'a}n G{\'o}mez and Juan Antonio Bueren and Glynn Thomas Faircloth and Beatriz Albella},
  journal={Toxicology in vitro : an international journal published in association with BIBRA},
  year={2003},
  volume={17 5-6},
  pages={
          671-4
        }
}
  • S. Gómez, J. Bueren, +1 author B. Albella
  • Published 2003
  • Biology, Medicine
  • Toxicology in vitro : an international journal published in association with BIBRA
Acute cytotoxic exposure causes decreases in bone marrow progenitors that precedes the neutrophil nadir. Experiments in animal models reveal a relationship between the reduction in granulocyte-macrophage progenitors (CFU-GM) and the decrease in absolute neutrophil count [Toxicol. Pathol. 21 (1993) 241]. Recently, the prevalidation of a model for predicting acute neutropenia by the CFU-GM assay has been reported [Toxicol. In Vitro 15 (2001) 729]. The model was based on prediction of human MTD by… Expand
A novel in vivo model for predicting myelotoxicity of chemotherapeutic agents using IL-3/GM-CSF transgenic humanized mice.
TLDR
It is demonstrated that the humanized mouse model can simultaneously evaluate myelotoxicity against human and mouse cells in vivo, and provides an effective preclinical tool for predicting appropriate doses of anticancer agents for clinical treatment. Expand
In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project.
TLDR
The results shown in the present study indicate that the sensitivity of CFU-GM progenitors correlates better than theensitivity of HL-60 cells with human LC50 values and could help to refine the predictability for human acute systemic toxicity when a given chemical may affect to the hematopoietic myeloid system. Expand
CFU-GM ASSSAY AS A DIAGNOSTIC TEST FOR TOXIC ASSESSMENT OF CHEMICALS
Pharmaceutical drugs, hazardous chemical compounds and other products must be evaluated for their hematological toxic potential for their safety use. In vitro CFU-GM clonogenic assay is one of theExpand
Compound-Specific Toxicities Detected in CFU-GM, Rat Kidney NRK Cells, Rat Bladder RBLAK Cells, and Rat Liver Slices following Batracylin or N-Acetyl Batracylin Exposure
TLDR
These studies demonstrated species similarities in sensitivity to BAT-induced myelosuppression, and implicate the metabolite NAB in biliary hyperplasia. Expand
Stem cells in myelotoxicity.
TLDR
There are three types of assays for hematopoietic progenitor clonogenic assays useable in myelotoxicology: CFU-GM assay for Colony Forming Unit Granulocyte and Macrophage, BFU-E assay for Burst Forming unit Erythroid, and CFU -MK assay for colony forming unit Megakaryocyte. Expand
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
TLDR
Application of the two-stage model-based trial design in Phase I programs with novel anti-cancer drugs that cause haematological toxicity is feasible, safe, and may lead to a reduction in the number of patient treated at sub-therapeutic dose-levels. Expand
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
TLDR
A two-stage model-based phase I design is safe for anticancer agents with dose-limiting myelosuppression and may enhance the efficiency of dose escalation studies by reducing the number of patients treated with a dose below the recommended dose and by increasing the precision of dose selection for phase II evaluation. Expand
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.
TLDR
The correlation (or lack thereof) between in vitro and in vivo immunotoxicity tests are considered as a mean to identify useful in vitro assays and are highlighted where predictability has been demonstrated for a variety of nanomaterials and assays with high potential for predictability in vivo. Expand
Novel Marine Compounds: Anticancer or Genotoxic?
TLDR
This review critically discusses importance of preclinical evaluation, failure of human clinical trials with certain potential anticancer agents, the screening tests used, and choice of biomarkers. Expand
Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents.
TLDR
The palladium compound [Pd2(C2,N-N-S(-)dmpa)2(mu-dppf)Cl2] (2) was able to inhibit Cathepsin B activity in a reversible fashion and was introduced as promising antitumoral drugs with reduced toxicity in experimental studies. Expand
...
1
2
...

References

SHOWING 1-10 OF 12 REFERENCES
Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning
TLDR
In clinical trial planning, in vitro colony-forming assays can be used to elucidate schedule dependency of myelotoxicity, to plan cytokine support, and to estimate dose-escalation effects. Expand
Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
TLDR
Results showed that the assay is linear under SOP conditions, and that the in vitro endpoints used by the clinical prediction model of neutropenia are highly reproducible within and between laboratories. Expand
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow.
TLDR
In vitro clonogenic assays of hematopoietic progenitors of myelotoxic agents can provide data that make both preclinical toxicology testing and clinical trial planning and interpretation more efficient and accurate, and quantitatively predict the AUCs at maximum tolerated dose in preclinical models and human patients. Expand
Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.
  • R. Parchment
  • Biology, Medicine
  • Environmental health perspectives
  • 1998
TLDR
In vitro hematotoxicology has developed rapidly during the past decade, and Pharmacologic principles critical for clinical predictions from in vitro data very likely will apply to toxicities to other proliferative tissues, such as mucositis. Expand
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
TLDR
In conclusion, ET-743 administered as a 24-h i.v. infusion at a dose of 1500 microg/m2 is clinically feasible; severe thrombocytopenia and neutropenia are the DLTs. Expand
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
TLDR
The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic, and Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile. Expand
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
TLDR
ET-743 has activity in advanced, highly pretreated STS and osteosarcoma patients and warrants further trials to establish the extent of its activity in this setting. Expand
Preserved long-term repopulation and differentiation properties of hematopoietic grafts subjected to ex vivo expansion with stem cell factor and interleukin 11.
TLDR
Results indicate that under optimized conditions of ex vivo expansion, the amplification of the hematopoietic progenitors responsible for the short- and mid-term repopulating properties of the graft can take place without compromising the long-term lympho-hematopoiesis of recipients. Expand
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
TLDR
Ecteinascidin 743 is the prototype for a distinct class of transcription-targeted chemotherapeutic agents and may be an efficacious adjuvant to the treatment of multidrug-resistant tumors. Expand
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
TLDR
It is found that Et743 interacts with the transcription-coupled NER machinery to induce lethal DNA strand breaks, and studies of cells deficient in XPC or in the genes implicated in Cockayne syndrome indicated that the drug sensitivity is specifically dependent on the transcription and NER pathway. Expand
...
1
2
...